Cornerstone Therapeutics, a specialty pharmaceutical company, has appointed Vincent Morgus as executive vice president (EVP), finance and chief financial officer (CFO). Morgus joins the company’s executive management team and will manage its finance function. He will report to Craig Collard, Cornerstone’s president and chief executive officer (CEO).
Morgus joins Cornerstone from Quintiles, where he has been senior vice president (SVP), corporate development since September 2003. He joined Quintiles in June 1994 and progressed through a variety of financial management positions within the Quintiles organisation, including vice president, finance of Quintiles Americas and CFO of Quintiles Informatics.
Prior to working at Quintiles, Morgus held controller positions at Q+E Software and DaVinci Systems. He started his career as an auditor for Arthur Andersen in northern California. Morgus earned his MBA from the University of North Carolina’s Kenan-Flagler Business School and his BSc from the Pennsylvania State University’s Smeal College of Business.
A report by broking group Marsh examines the repercussions from the administration of the South Korean company, which filed for bankruptcy protection at the end of August.
Global research by C2FO suggests that smaller businesses are less concerned with the repercussions of Brexit and the upcoming US presidential election.
A squeeze on skilled talent means it now takes an average of seven weeks to fill open permanent roles in finance in the UK according to new research from financial services recruitment firm Robert Half.
Early-stage merger and acquisition deals in Asia-Pacific show nearly 10% year-on-year growth in recent months.